Introduction {#s1}
============

Breast cancer does not exclusively affect females. Around 300 men in the UK and 1,900 men in the US are diagnosed with the disease each year [@pgen.1002290-Jemal1]. The average age at incidence of male breast cancer is somewhat different to that seen for female breast cancer, with the disease typically affecting men 5--10 years later than women. Perhaps because male breast cancer is not common, few risk factors have been demonstrated to influence disease risk, but tentative associations with obesity, lack of exercise, excess alcohol consumption, gynaecomastia, past benign breast disease, past liver disease, infertility, diabetes and exposure to ionising radiation have been suggested [@pgen.1002290-Sasco1], [@pgen.1002290-Weiss1].

Investigation of susceptibility genes for male breast cancer has been limited. It has however been shown that approximately 10% of men with breast cancer carry *BRCA2* mutations, while mutations in *BRCA1* are exceedingly rare [@pgen.1002290-GomezRaposo1]. The relative risk of breast cancer in men associated with *BRCA2* mutations is high [@pgen.1002290-Thompson1]. Recently the *CHEK2* 1100delC variant has been found to give a 10-fold risk of male breast cancer independent of *BRCA1* or *BRCA2* [@pgen.1002290-MeijersHeijboer1]. Mutations in these genes are rare in the general population and it is likely that much of the genetic contribution to female breast cancer risk can be attributed to the co-inheritance of multiple low risk common variants [@pgen.1002290-Fletcher1]. Recent genome-wide association studies (GWAS) have shown associations between single nucleotide polymorphisms (SNPs) mapping to a dozen or more loci and female breast cancer risk in European populations, each conferring odds ratios (ORs) of 1.04--1.43 [@pgen.1002290-Ahmed1]--[@pgen.1002290-Turnbull1]. To explore the possibility that the same risk variants influence male breast cancer risk, we conducted a case-control study of male breast cancer, genotyping 12 SNPs annotating the loci that have the strongest and most consistent associations with female breast cancer.

Materials and Methods {#s2}
=====================

457 cases of male breast cancer were recruited in a population-based case-control study of the genetic, environmental and behavioral causes of male breast cancer being conducted in England and Wales. Potential cases were all men resident in these countries aged 18--79 with newly diagnosed breast cancer since January 1^st^, 2005, identified through notifications by treatment centres and systematic regular listings of cases from regional cancer registries. 98% of cases for whom registry data has been received have been histologically confirmed. The median age at diagnosis of cases was 65.5 years (interquartile range: 59--72).

A total of 1608 unmatched controls were available for genotyping; 535 men were ascertained through our ongoing breast cancer studies and a further 1073 were healthy male and female individuals from the UK Genetic Lung Cancer Predisposition Study (GELCAPS) [@pgen.1002290-Eisen1]. The decision to include a second control set was made *a priori*, with the aim of increasing statistical power. We saw no evidence for an effect of control group on the overall effect estimate for each SNP. Collection of blood samples from all subjects was undertaken with informed consent and relevant ethical review committee approval.

DNA was extracted from venous blood samples using conventional methodologies and quantified by Picogreen (Invitrogen, Carlsbad CA). SNPs were chosen for analysis on the basis of validated associations with female breast cancer from recent GWAS [@pgen.1002290-Ahmed1]--[@pgen.1002290-Turnbull1]. Genotyping of rs11249433, rs13387042, rs4973768, rs10941679, rs16886165, rs9383938, rs13281615, rs865686, rs2981579, rs3817198, rs3803662 and rs6504950 was performed by allele-specific PCR using KASPar chemistry (Kbioscience, Hertfordshire, UK). Each DNA plate contained 5% sample duplication to assess genotyping concordance between duplicate pairs. We attempted to genotype 2119 samples (including duplicates, n = 54) and excluded samples (n = 49; 11 cases, 34 controls and four members of a duplicate pair) in which no-calls were observed for two or more SNPs. Genotyping QC statistics were therefore computed on 2070 samples ([Figure S1](#pgen.1002290.s001){ref-type="supplementary-material"}). Final locus and sample completion rates were \>99.9%. The mean genotype concordance between duplicate pairs was 99.8%. We excluded a further 18 subjects due to self-reported non-European ancestry (13 cases and 5 controls). No SNP genotypes showed significant deviation from the proportions expected under Hardy-Weinberg equilibrium in controls ([Table S1](#pgen.1002290.s002){ref-type="supplementary-material"}).

ORs and 95% confidence intervals (CI) were calculated using unconditional logistic regression. The odds ratio for each SNP was determined by fitting multiplicative and unconstrained genetic models. P-values were computed from likelihood ratio test statistics. Case-only unconditional logistic regression was used to test the significance of association with age at diagnosis. Deviation of genotype proportions from Hardy-Weinberg equilibrium was assessed in controls using an exact test [@pgen.1002290-Wigginton1]. To compare formally the ORs in males with the equivalent published ORs for female disease, we assumed both sets of ORs were log-normally distributed. Then under the null hypothesis that the OR in males is equal to the OR in females, the difference between the estimated log ORs is normally distributed with mean zero and variance equal to the sum of the squared standard errors of the two estimates. From this we obtained a **χ^2^** statistic for each comparison (1 degree of freedom \[d.f.\]) and from the sum of the **χ^2^** statistics a global test for all comparisons (12 d.f.). Statistical analyses were performed using the Genotype Libraries and Utilities (GLU) package (<http://code.google.com/p/glu-genetics>) and R [@pgen.1002290-Team1].

Results/Discussion {#s3}
==================

433 male breast cancer cases and 1569 controls were successfully genotyped according to our predefined QC criteria. The majority of cases were diagnosed with invasive breast cancer (n = 399 (92%)) while a further 31 (7%) were ductal carcinoma in situ. Three cases (\<1%) were of unknown histology. [Table 1](#pgen-1002290-t001){ref-type="table"} shows the OR for male breast cancer associated with each of the 12 SNPs previously reported to be associated with female breast cancer risk. For five SNPs, rs13387042 (2q35), rs10941679 (5p12), rs9383938 (6q25.1), rs2981579 (*FGFR2*) and rs3803662 (*TOX3*), the risk allele for female breast cancer was associated with increased risk of male breast cancer (p\<0.05). Two SNPs, rs13387042 (2q35) and rs3803662 (*TOX3*), remained significant below the Bonferroni adjusted threshold for independent tests of p\<4.12×10^−3^.

10.1371/journal.pgen.1002290.t001

###### Risk estimates for male breast cancer conferred by 12 loci identified through GWAS of female breast cancer.

![](pgen.1002290.t001){#pgen-1002290-t001-1}

  SNP           Chromosome     Gene     Risk Allele[a](#nt101){ref-type="table-fn"}   Risk Allele Freq   Male breast cancer   Female breast cancer[b](#nt102){ref-type="table-fn"}                                                                                          
  ------------ ------------ ---------- --------------------------------------------- ------------------ -------------------- ------------------------------------------------------ -------------- -------------- --------------------------------------------------------- --------------
  rs11249433      1p11.2     *NOTCH2*                        C                              0.42                1.07                                  1.28                               1.12           0.13                    1.20 [@pgen.1002290-Thomas1]                 4.48−10^−13^
                                                                                                            (0.84--1.36)                          (0.94--1.73)                       (0.97--1.31)                                       (1.14--1.25)                        
  rs13387042       2q35                                      A                              0.50                1.31                                  1.69                               1.30       7.98−10^−04^                 1.12 [@pgen.1002290-Milne1]                 1.00−10^−19^
                                                                                                            (1.00--1.73)                          (1.24--2.29)                       (1.11--1.51)                                       (1.09--1.15)                        
  rs4973768       3p24.1     *SLC4A7*                        T                              0.47                1.05                                  1.28                               1.13           0.11                     1.11 [@pgen.1002290-Ahmed1]                 1.40−10^−18^
                                                                                                            (0.81--1.36)                          (0.95--1.74)                       (0.97--1.32)                                       (1.08--1.13)                        
  rs10941679       5p12                                      G                              0.27                1.28                                  1.54                               1.26          0.007                    1.19 [@pgen.1002290-Stacey1]                 2.90−10^−11^
                                                                                                            (1.02--1.60)                          (1.04--2.29)                       (1.07--1.48)                                       (1.13--1.26)                        
  rs16886165      5q11.2     *MAP3K1*                        G                              0.16                0.99                                  0.85                               0.97           0.77                    1.23 [@pgen.1002290-Thomas1]                 5.00−10^−07^
                                                                                                            (0.78--1.26)                          (0.41--1.78)                       (0.79--1.19)                                       (1.12--1.35)                        
  rs9383938       6q25.1      *ESR1*                         T                              0.09                1.31                                  2.79                               1.39           0.01                   1.18 [@pgen.1002290-Fletcher2]                1.41−10^−07^
                                                                                                            (0.99--1.73)                          (1.11--7.00)                       (1.09--1.78)                                       (1.11--1.26)                        
  rs13281615     8q24.21                                     G                              0.41                0.97                                  1.20                               1.07           0.37                    1.08 [@pgen.1002290-Easton1]                 5.00−10^−12^
                                                                                                            (0.76--1.23)                          (0.88--1.64)                       (0.92--1.25)                                       (1.05--1.11)                        
  rs865686        9q31.2                                     T                              0.62                1.07                                  1.10                               1.04           0.62                    1.11[@pgen.1002290-Fletcher2]                1.75−10^−10^
                                                                                                            (0.77--1.49)                          (0.78--1.53)                       (0.89--1.22)                                       (1.04 -1.19)                        
  rs2981579      10q26.13    *FGFR2*                         T                              0.42                1.06                                  1.43                               1.18           0.03       1.26 [@pgen.1002290-Easton1], [@pgen.1002290-Turnbull1]   2.00−10^−76^
                                                                                                            (0.83--1.36)                          (1.06--1.94)                       (1.02--1.38)                                       (1.23--1.30)                        
  rs3817198      11p15.5      *LSP1*                         C                              0.32                0.94                                  0.87                               0.93           0.39                    1.07 [@pgen.1002290-Easton1]                 3.00−10^−09^
                                                                                                            (0.75--1.89)                          (0.60--1.25)                       (0.79--1.09)                                       (1.04 -1.11)                        
  rs3803662      16q12.1      *TOX3*                         T                              0.27                1.48                                  2.21                               1.48       4.04−10^−06^                1.20 [@pgen.1002290-Easton1]                 1.00−10^−36^
                                                                                                            (1.18--1.85)                          (1.50--3.25)                       (1.26--1.75)                                       (1.16--1.24)                        
  rs6504950       17q22      *COX11*                         G                              0.72                0.86                                  0.79                               0.90           0.22                     1.05 [@pgen.1002290-Ahmed1]                 1.40×10^−08^
                                                                                                            (0.58--1.28)                          (0.53--1.17)                       (0.76--1.06)                                       (1.03--1.07)                        

Risk allele for female breast cancer.

Female association statistics and effect estimates from previously published data.

Comparing OR~male~ estimates with those for female breast cancer (OR~female~) there were two SNPs, rs13387042 (2q35) and rs3803882 (*TOX3*) for which the OR~male~ was significantly higher than the OR~female~, albeit not after adjusting for multiple testing (rs13387042, OR~male~:OR~female~ p = 0.03; rs3803882, OR~male~:OR~female~ p = 0.04; [Table 2](#pgen-1002290-t002){ref-type="table"}). rs3803662 (*TOX3*) showed the strongest association with male breast cancer (OR~male~  = 1.48; 95% CI 1.26--1.75, p = 4.04×10^−6^) with an excess relative risk that was more than twice the female estimate (OR~female~  = 1.20; 95% CI 1.16--1.24) [@pgen.1002290-Easton1]. Similarly, the excess risk conferred by rs13387042 (2q35) in males (OR~male~  = 1.30; 95% CI 1.11--1.51, p = 7.98×10^−4^) was more than double that observed in females (OR~female~  = 1.12; 95% CI 1.09--1.15) [@pgen.1002290-Milne1].

10.1371/journal.pgen.1002290.t002

###### Ratio of OR~male~:OR~female~ for 12 risk loci identified by genome-wide association studies of female breast cancer.

![](pgen.1002290.t002){#pgen-1002290-t002-2}

  SNP                      Chromosome   OR~male~:OR~female~ (95% CI)     χ^2^     P-value[a](#nt103){ref-type="table-fn"}
  ----------------------- ------------ ------------------------------ ---------- -----------------------------------------
  rs11249433                 1p11.2          0.95 (0.80--1.11)          0.425                      0.50
  rs13387042                  2q35           1.19 (1.01--1.39)          4.538                      0.03
  rs4973768                  3p24.1          1.07 (0.91--1.25)          0.681                      0.41
  rs10941679                  5p12           1.03 (0.86--1.22)          0.087                      0.77
  rs16886165                 5q11.2          0.81 (0.65--1.02)          3.116                      0.08
  rs9383938                  6q25.1          1.22 (0.95--1.58)          2.400                      0.12
  rs13281615                8q24.21          1.02 (0.87--1.20)          0.036                      0.85
  rs865686                   9q31.2          0.95 (0.80--1.13)          0.293                      0.59
  rs2981579                 10q26.13         0.96 (0.82--1.12)          0.315                      0.57
  rs3817198                 11p15.5          0.87 (0.74--1.03)          2.646                      0.10
  rs3803662                 16q12.1          1.19 (1.01--1.42)          4.118                      0.04
  rs6504950                  17q22           0.84 (0.71--0.99)          4.086                      0.04
  **All SNPs combined**                          **22.769**            **0.03**  

P value for null hypothesis of no difference between OR~male~ and OR~female~ for each SNP individually and for all SNPs combined (in bold).

For one SNP (rs6504950, *COX11*) the OR~male~ was in the opposite direction to that reported for female breast cancer (OR~male~  = 0.90; 95% CI 0.76--1.06, OR~female~  = 1.05; 95% CI 1.03--1.07) [@pgen.1002290-Ahmed1], [@pgen.1002290-Easton1] and was inconsistent with the female estimate (OR~male~:OR~female~ p = 0.04; [Table 2](#pgen-1002290-t002){ref-type="table"}). For the other nine SNPs that we tested the OR~male~ estimates were consistent with the OR~female~ estimates. Comparing the combined estimates of all 12 SNPs, however, there was nominal evidence that the male ORs differed from the female ORs (p = 0.03; [Table 2](#pgen-1002290-t002){ref-type="table"}).

The frequency of female breast tumors that are estrogen receptor (ER) positive varies, particularly according to menopausal status at diagnosis [@pgen.1002290-Clark1]. Based on a sample of almost 3,000 patients the proportion is typically between 64% and 79% [@pgen.1002290-Clark1]. In contrast, male breast tumors, tend to be overwhelmingly ER-positive (\>90%) [@pgen.1002290-Willsher1]. In the current study estrogen receptor status was known for 251 male breast cancer cases, 246 (98%) of which had ER-positive tumors. For nine of the 12 SNPs that we genotyped, OR~female~ estimates stratified according to ER status have been reported for Caucasian populations ([Tables S2a and S2b](#pgen.1002290.s003){ref-type="supplementary-material"}). In females, the OR for ER-positive disease is stronger than the OR for ER-negative disease for all nine of these loci and this difference is significant for all but two of them (rs16886165 (*MAP3KI*) and rs3817198 (*LSP1*) [@pgen.1002290-Ahmed1], [@pgen.1002290-Milne1], [@pgen.1002290-GarciaClosas1]. Given the predominance of ER-positive tumors in male disease we also compared the OR~male~ with the OR~female~ for ER-positive disease ([Table S2a](#pgen.1002290.s003){ref-type="supplementary-material"}). There was nominally significant evidence overall that the male ORs differed from those for ER-positive female disease (p = 0.05). We also tested for a difference between the OR~male~ estimates for these nine SNPs and the OR~female~ estimates for ER-negative disease ([Table S2b](#pgen.1002290.s003){ref-type="supplementary-material"}); there was stronger evidence of a difference (p = 0.01).

Finally, we assessed the relationship between genotype and age at onset of male breast cancer ([Table S3](#pgen.1002290.s004){ref-type="supplementary-material"}) for each of the 12 loci. There was no evidence for a trend with age at diagnosis.

We have shown, for the first time that common genetic variants influence susceptibility to male breast cancer. Furthermore we have demonstrated that for at least a subset of known susceptibility loci the risk allele for female breast cancer is also associated with increased risk of disease in males. To our knowledge these 433 male breast cancer cases represent the largest single series to date; despite this, we lacked power to detect modest relative risks for all but the most common variants. For example we had only 40% power to detect an OR of 1.15 for a variant with a minor allele frequency of 30% at a significance level of 5%. The lack of a statistically significant association with male breast cancer risk for seven of the 12 SNPs that we tested may, therefore, simply reflect a lack of power.

Notably, for two of the three SNPs for which the OR~male~ was inconsistent with the OR~female~ (rs13387042 (2q35) and rs3803882 (*TOX3*)) the association in males was stronger than that in females. While the OR~male~ estimates were slightly closer to the ORs for ER-positive disease in females, it is noticeable that these are the two SNPs that show the largest effects on ER-negative disease risk in females. Although the significance of this observation, if any, is not yet clear, our data on male breast cancer alongside the published associations with female breast cancer, clearly implicate the 2q35 and 16q12.1 loci in the aetiology of breast cancer, irrespective of gender and tumor pathology.

Given that the majority of female breast cancer risk loci identified to date demonstrate a degree of specificity for ER-positive or ER-negative disease [@pgen.1002290-Ahmed1], [@pgen.1002290-Milne1], [@pgen.1002290-GarciaClosas1], [@pgen.1002290-Antoniou1] it seems likely that subtype specific GWAS will lead to the identification of additional risk loci. Our analyses suggest that GWAS of male breast cancer may also lead to the identification of novel breast cancer risk loci in males and that these should provide further insight into the biological basis of male and female breast cancer development.
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